There are two approved drug and over 150 product candidates, which are being evaluated for the treatment of a variety of disease indications Knowpia

Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

The USD 9.2 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:

§ Key therapeutic areas

§ Oncological disorders

§ Infectious diseases

§ Genetic disorders

§ Ophthalmic disorders

§ Hepatic disorders

§ Respiratory disorders

§ Type of RNAi molecule

§ siRNA

§ miRNA

§ shRNA

§ sshRNA

§ DNA

§ Route of administration

§ Subcutaneous

§ Intravenous

§ Intradermal

§ Intratumoral

§ Intravitreal

§ Oral

§ Intramuscular

§ Key geographical regions

§ North America

§ Europe

§ Asia Pacific and the Rest of the World

§ Leading Players

The RNAi Therapeutics Market (2^nd Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:

§ Quark Pharmaceuticals

§ Alnylam Pharmaceuticals

§ Dicerna Pharmaceuticals

§ Souzhou Ribo Life Sciences

§ Olix Pharmaceuticals

§ Sirnaomics

§ Ariz Precision Medicine

§ Arrowhead Pharmaceuticals

§ Gradalis

§ Benitec Biopharma

Table of Contents

1. PREFACE